Want to see HK:1696 full AI Analyst Report?
1696 Stock Chart & Stats
HK$3.87
-HK$0.01(-0.28%)
At close: 4:00 PM EST
HK$3.87
-HK$0.01(-0.28%)
Day’s Range― - ―
52-Week RangeHK$1.71 - HK$4.91
Previous CloseN/A
Volume75.47K
Average Volume (3M)236.42K
Market Cap
HK$845.36M
Enterprise ValueHK$2.01B
Total Cash (Recent Filing)HK$77.27M
Total Debt (Recent Filing)HK$78.87M
Price to Earnings (P/E)9.4
Beta0.98
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.26%
Share Statistics
EPS (TTM)0.02
Shares Outstanding468,343,080
10 Day Avg. Volume493,740
30 Day Avg. Volume236,420
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.66
Revenue Forecast (FY)HK$3.17B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and continued equity growth give Sisram Medical financial resilience and flexibility. A conservative capital structure reduces balance-sheet risk, supports continued investment in products and services, and provides greater capacity to manage fluctuations in demand or profitability.
Recurring Installed-base RevenueThe installed-base model supplements one-time equipment sales with consumables, service, maintenance, and training revenue. As deployed systems are used over time, these recurring streams can improve customer retention, diversify revenue, and make the business less dependent on new capital-equipment purchases.
Revenue Growth And Gross MarginMulti-year revenue growth indicates that Sisram Medical has continued expanding its business, while a gross margin near 59% shows meaningful economic value remains in its products. This combination can support reinvestment and operating leverage if growth and cost control improve.
Bears Say
Material Margin CompressionThe sharp decline in net margin shows that revenue growth is currently converting into substantially less profit than in earlier periods. Higher costs and/or pricing pressure could remain a durable constraint, reducing reinvestment capacity and weakening earnings resilience even if sales continue to expand.
Weakened Cash GenerationThe steep 2025 decline in operating and free cash flow indicates weaker cash conversion and reduces internally generated funding for growth, dividends, or investment. Although free cash flow remained positive, the deterioration raises concern that earnings are not translating consistently into available cash.
Declining Earnings MomentumA substantial decline in EPS, alongside lower return on equity, signals that the company is currently generating less shareholder profit from its capital base. If this persists, it can limit the effectiveness of the strong balance sheet and weaken the sustainability of future earnings growth.
Sisram Medical Ltd. News
1696 FAQ
What was Sisram Medical Ltd.’s price range in the past 12 months?
Sisram Medical Ltd. lowest stock price was HK$1.71 and its highest was HK$4.91 in the past 12 months.
What is Sisram Medical Ltd.’s market cap?
Sisram Medical Ltd.’s market cap is HK$845.36M.
When is Sisram Medical Ltd.’s upcoming earnings report date?
Sisram Medical Ltd.’s upcoming earnings report date is Mar 24, 2027 which is in 144 days.
How were Sisram Medical Ltd.’s earnings last quarter?
Sisram Medical Ltd. released its earnings results on Aug 19, 2026. The company reported -HK$0.02 earnings per share for the quarter.
Is Sisram Medical Ltd. overvalued?
According to Wall Street analysts Sisram Medical Ltd.’s price is currently Overvalued.
Does Sisram Medical Ltd. pay dividends?
Sisram Medical Ltd. pays a Annually dividend of HK$0.095 which represents an annual dividend yield of 5.26%. See more information on Sisram Medical Ltd. dividends here
What is Sisram Medical Ltd.’s EPS estimate?
Sisram Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sisram Medical Ltd. have?
Sisram Medical Ltd. has 468,343,080 shares outstanding.
What happened to Sisram Medical Ltd.’s price movement after its last earnings report?
Sisram Medical Ltd. reported an EPS of -HK$0.02 in its last earnings report. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Sisram Medical Ltd.?
Currently, no hedge funds are holding shares in HK:1696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sisram Medical Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.20%
12-Months-Change
Fundamentals
Return on Equity
2.40%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sisram Medical Ltd.
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.
Technical Analysis
Peijia Medical Ltd.
―
Yestar Healthcare Holdings Co Ltd
―
Gaush Meditech Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Austar Lifesciences Ltd.
―